MAR 15·Simply Wall StMed
Surgery Partners (SGRY) Is Down 7.3% After Soft 2026 Outlook, Buyback Launch, and New Director
Surgery Partners (SGRY) shares fell 7.3% following its 2026 outlook, which included softer revenue guidance ($3.35B-$3.45B), despite reporting higher 2025 sales and launching a new $200 million share repurchase program. The company also appointed Lloyd Dean as an independent director while facing pressure from activist investor Ortelius Advisors. These developments intensify scrutiny on Surgery Partners' capital allocation, governance, and execution plans, especially given its ongoing net losses and significant debt.